The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Hoechst Marion Roussel
Approval Status: Approved March 1998
Treatment for: heparin-induced thrombocytopenia type II
General Information
Refludan has been approved for the treatment of heparin-induced thrombocytopenia type II (HIT type II). HIT type II is a rare, allergy-like adverse reaction to heparin, a standard anticoagulant therapy. HIT type II is characterized by a rapid and serious decline in the blood's platelet count, leading to an increased risk of severe thromboembolic complications.
